Rachel N. Grisham, MD

Articles

Dr Grisham on the Efficacy of Avutometinib Plus Defactinib in Gynecologic Mesonephric Cancer

March 16th 2025

Rachel N. Grisham, MD, discusses the efficacy of avutometinib plus defactinib in patients with advanced or recurrent gynecologic mesonephric cancer.

Dr. Grisham on the Combination of VS-6766 With Defactinib in Ovarian Cancer

August 24th 2021

Rachel N. Grisham, MD, discusses the rationale to explore the combination of VS-6766 and defactinib in patients with low-grade serous ovarian cancer.

Dr. Grisham on the Rationale for Binimetinib in Low-Grade Serous Ovarian Cancer

August 19th 2021

Rachel N. Grisham, MD, discusses rationale for evaluating binimetinib as a treatment option for patients with low-grade serous ovarian cancer.

Dr. Grisham on the Mechanism of Action of VS-6766 in Recurrent Low-Grade Serous Ovarian Cancer

March 19th 2021

Rachel N. Grisham, MD, discusses the mechanism of action of VS-6766 in patients with recurrent low-grade serous ovarian cancer.

Dr. Grisham on MEK Inhibition in Low-Grade Serous Ovarian Cancer

February 27th 2019

Rachel N. Grisham, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses MEK inhibition in the treatment of patients with low-grade serous ovarian cancer.

Dr. Grisham on Frontline Treatment for Low-Grade Serous Ovarian Cancer

February 5th 2019

Rachel N. Grisham, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses frontline treatment options for patients with low-grade serous ovarian cancer.